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CASE REPORT
First report of multi-drug resistant 
tuberculosis in a systemic lupus erythematosus 
patient
Kunchok Dorjee1,3*, Kerry L Dierberg2, Tsetan D Sadutshang3 and Arthur L Reingold1
Abstract 
Background: Treatment of a multi-drug resistant tuberculosis (MDR-TB) patient is clinically challenging, requiring a 
minimum of 18 months of therapy. Its occurrence in a systemic lupus erythromatosus (SLE) patient may complicate 
management of both MDR-TB and SLE. This is the first descriptive report of MDR-TB in an SLE patient.
Case presentation: A 19-year old female receiving long-term prednisolone for SLE was diagnosed with MDR-TB. She 
was started on MDR-TB treatment regimen and prednisolone was replaced with azathioprine. After an initial response 
to therapy, patient experienced a flare of lupus symptoms. Imaging studies revealed avascular necrosis of right femo-
ral head. She was then treated with intravenous methyl-prednisolone, followed by maintenance corticosteroid. Aza-
thioprine was discontinued due to hematological toxicity and failure to control SLE. Her symptoms of lupus regressed 
and did not re-occur for the duration of her MDR-TB treatment. Patient was declared cured of MDR-TB after 18 months 
of ATT. She is currently scheduled for a total hip replacement surgery.
Conclusions: This case highlights the challenges of simultaneously managing MDR-TB and SLE in a patient due to 
their over-lapping signs and symptoms, drug–drug interactions, and the need for use of immunomodulatory agents 
in the absence of standard guidelines and documented previous experiences. Our experience underscores the impor-
tance of appropriate selection of treatment regimens for both MDR-TB and SLE.
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Background
Systemic lupus erythematosus is a chronic autoim-
mune disease. TB incidence and mortality rate are high 
in SLE patients [1, 2]. With the surge of drug resistant 
TB globally, more SLE patients may develop MDR-TB 
[3]. Through this case report, we have shown a success-
ful management of an MDR-TB case in an SLE patient, 
despite initial treatment challenges.
Case presentation
In November 2010, a 19-year-old ethnically Tibetan 
female with SLE was referred to us with sputum culture 
and drug susceptibility test (DST) results, which demon-
strated multi-drug resistant pulmonary TB with resist-
ance to isoniazid, rifampicin, ethambutol, streptomycin, 
ethionamide and susceptibility to kanamycin, capreomy-
cin, ofloxacin, moxifloxacin, pyrazinamide, para-amino-
salicylic acid and clofazimine. While there was no clear 
history of contact with TB cases, she was residing in a 
boarding school where cases of MDR-TB have occurred 
over the past few years. Prior to receiving the DST result, 
she had taken category I anti-tubercular treatment (ATT) 
with isoniazid, rifampicin, pyrazinamide, and ethambutol 
for 45  days without response. She presented to us with 
fever, cough, and generalized weakness and was sputum 
smear positive for acid-fast bacilli. Chest radiograph 
demonstrated bilateral upper and mid-lung infiltrates 
with cavitary lesions (Fig. 1).
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In 2006, she was diagnosed with SLE after present-
ing with malar rash, photosensitivity, and polyserositis 
(pleural effusion, pericardial effusion, ascites). Tests for 
anti-nuclear antibody and anti-double stranded DNA 
antibody were positive. Since then, she had been on 
methyl prednisolone and hydroxychloroquine (HCQ). 
For the year prior to presentation she was taking methyl 
prednisolone 8  mg on alternate days and HCQ 200  mg 
twice daily.
On November 24, 2010, we started MDR-TB treat-
ment with kanamycin 600  mg, levofloxacin 750  mg, 
para-aminosalicylic acid 8 g, cycloserine 750 mg, pyrazi-
namide 1,250  mg, and clofazimine 100  mg. Her weight 
was 42 kg. A dose reduction of methyl prednisolone was 
initiated and azathioprine 50 mg was introduced, with a 
plan to gradually increase the dose to 100–125 mg. After 
gradual taper, methyl prednisolone was stopped after 
30 days. Her symptoms initially improved with resolution 
of fever and subsidence of cough. Sputum-smear became 
negative. However, after 2  months of MDR-TB therapy, 
she complained of difficulty walking with right hip pain 
radiating to the knee, worse with movement, and had 
developed a limp. On examination, there was notable 
shortening of right lower extremity with muscle wasting 
in the thighs and legs. In a week’s time, she developed 
butterfly rash on her cheeks, alopecia, and increased dif-
ficulty in walking. Radiograph of the hip-joints showed 
lytic and sclerotic lesions of the right femoral head with 
irregular contour (Fig. 2). MRI of the hip-joints showed 
avascular necrosis of bilateral femoral heads, right 
greater than left, with minimal effusion of right hip-
joint. Her hemoglobin had dropped from 12 to 7.9 gm% 
and platelet count had dropped from 260,000 to 68,000/
µl. She was referred for multi-disciplinary consultation, 
which revealed no evidence of central nervous system 
involvement or lupus nephritis. Methyl prednisolone IV 
pulse therapy was started, followed by an oral predniso-
lone taper. Azathioprine was stopped in view of possible 
myelosuppression resulting in anemia and thrombocy-
topenia. The patient clinically improved, with resolution 
of the skin rash and arthralgias. She was put on mainte-
nance prednisolone dose of 7.5 mg, HCQ 200 mg twice 
daily, calcium supplements and once-weekly alendronate 
with vitamin D3. MDR-TB treatment was continued. Two 
months after stopping Azathioprine, her hemoglobin 
level and platelet count had increased to 10.1 gm% and 
139,000/µl respectively. During follow up orthopedic 
consultations, no progression of osteonecrosis of hip 
joint was observed, and total hip joint replacement was 
recommended after completion of MDR-TB treatment. 
Injection kanamycin was stopped after 9 months of ATT 
and pyrazinamide was stopped after 1 year of ATT. Con-
secutive sputum smears were negative. She had seven 
negative cultures for TB since the start of MDR-TB treat-
ment. After 18  months of ATT, she was declared cured 
and TB treatment was stopped. She is currently being 
planned for a hip replacement surgery.
Discussion
To our knowledge, this is the first reported case of MDR-
TB in an SLE patient. Immunosuppression from chronic 
steroid therapy and living in a high TB and MDR-TB 
prevalence area were important risk factors for devel-
opment of MDR-TB in our SLE patient. A high rate of 
MDR-TB has been previously reported in the Tibetan 
Fig. 1 Chest radiograph showing bilateral upper and mid-lung 
infiltrates due to MDR-TB in a patient suffering from SLE.
Fig. 2 Radiograph showing elevated right hemipelvis and irregular 
contour of right hip-joint with lytic and sclerotic lesions in the femoral 
head in an SLE patient diagnosed with MDR-TB.
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population living in India [4]. Diagnosis and management 
of TB and especially MDR-TB in an SLE patient pose sev-
eral challenges. We think there are four major points to 
highlight: (1) Signs/symptoms of TB and SLE can mimic 
each other posing a diagnostic challenge, (2) Drug toxici-
ties of MDR-TB treatment, including skin rash, arthral-
gias, nephrotoxicity, anemia, thrombocytopenia and 
CNS symptoms could also mimic signs/symptoms of 
SLE and thus complicate management, (3) Drug-drug 
interactions and overlapping toxicities can complicate 
management of SLE and MDR-TB, especially in the face 
of mycobacterial resistance to fluoroquinolones and/or 
aminoglycosides where more toxic drugs like linezolid 
may have to be used, which share similar hematological 
toxicity profile with immuno-suppressive agents such as 
azathioprine used for SLE [5], and (4) Absent clear-cut 
guidelines, use of immunosuppressant agents and their 
dose adjustments in an SLE patient with MDR-TB could 
be clinically challenging for the treating physician.
In this patient, the hip joint involvement could be 
either due to long-term steroid therapy, osteonecrosis 
from SLE or MDR-TB of hip-joint, though the revela-
tion of avascular necroses of bilateral femoral heads on 
MRI, and development of leg/joint pains while receiving 
ATT suggested chronic steroid therapy as the etiology. 
It was difficult to clearly distinguish between chronic 
steroid therapy and SLE as the cause. We had some con-
cern with the use of pyrazinamide given her hip-joint 
involvement and leg pain since pyrazinamide can lead 
to hyperuricemia and arthralgias [6]. However, since our 
patient’s symptoms subsided soon after re-introduction 
of corticosteroid, we decided to continue with pyrazina-
mide for a year, carefully weighing the risks and benefits. 
Our patient was fortunate in that she was susceptible to 
the core second-line anti-TB drugs: fluoroquinolones 
and aminoglycosides. The SLE flare she experienced dur-
ing the course of MDR-TB treatment was likely due to 
the attempted withdrawal of glucocorticoid rather than 
worsening TB given her initial improvement after MDR-
TB treatment, continued sputum-smear negativity, and 
the rapid response to restarting glucocorticoid. Through 
out the treatment course, we were vigilant of any signs 
and symptoms of neuropsychiatric lupus such as depres-
sion, since our patient was also receiving cycloserine 
for MDR-TB that can also cause depression and trigger 
suicidal tendencies [7]. In summary, given the docu-
mented poorer outcomes of MDR-TB treatment in other 
immuno-compromised states [8, 9], it becomes impor-
tant that initiation and dose adjustment of corticoster-
oids and immuno-suppressants for SLE are cautiously 
done taking care to maintain appropriate response to 
ATT and also achieve a sustained remission of SLE. 
Additionally, due to overlapping drug toxicities, meticu-
lous selection of MDR-TB treatment regimen in an SLE 
patient is important.
Conclusion
Although SLE and MDR-TB may be a rare combination, 
rise of global incidence of MDR-TB may mean that cli-
nicians worldwide will encounter more such cases [5]. It 
is important to holistically evaluate the risks and benefits 
while selecting the treatment components for MDR-TB 
and SLE. Use of low-dose maintenance corticosteroid 
was necessary for control of SLE in our patient and it did 
not adversely affect the MDR-TB treatment outcome. 
Frequent and close monitoring is very important. Phar-
macological management should be individualized to 
achieve optimum disease control with minimum adverse 
drug events. Developing guidelines for managing MDR-
TB in the presence of chronic conditions such as SLE 
would help clinicians and patients worldwide.
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